BP43131: A phase 1 study to test the safety and efficacy of RO7443904 in combination with glofitamab in people with relapsed or refractory B-cell non-Hodgkin lymphoma
A phase 1 trial testing the safety of a treatment combination in people whose B-cell non-Hodgkin lymphoma has either relapsed or didn’t respond to previous treatment.
You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT05219513
Trial aim and background
The aim of this trial is to find out the maximum tolerated dose for the combination of RO7443904 and glofitamab in those who have relapsed (come back after treatment) or refractory (didn’t respond to previous treatment) B-cell non-Hodgkin lymphoma.
This is a phase 1 (early phase) trial. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment, but the trial will give important information about this new treatment, which could help other people in the future.
Who can enter
Adults with B-cell non-Hodgkin lymphoma which has relapsed after, or failed to respond to two prior treatment regimens.
Locations
Recruitment is taking place at the Leicester Royal Infirmary, Leicester
Further information
More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/ct2/show/study/NCT05219513
Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.